Analysis of Veno-Venous Extracorporeal Membrane Oxygenation for COVID-19 Compared to Non-COVID Etiologies
Main finding · In-hospital mortalityResult — go to the resultAdjusted odds ratio 2.03 95% CI 1.87–2.20Authors' conclusion
In this nationwide analysis, COVID-19 patients with ARDS requiring V-V ECMO support had increased mortality compared with patients who underwent V-V ECMO for non-COVID etiologies.
Study context
- Population
- Patients undergoing V–V extracorporeal membrane oxygenation (ECMO) at US academic centres, identified by ICD-10 codes, April 2020–December 2022
- Participants
- 6,040 vs 6,382
- Exposure
- Veno-venous (V-V) ECMO for COVID-19 acute respiratory distress syndrome (ARDS) vs V-V ECMO for non-COVID causes
- COVIDn = 6,040
- non-COVIDn = 6,382reference
- Outcome
- In-hospital mortality
Methodological detailsmultivariate logistic regression, US academic centres
- Multivariate logistic regression
- US academic centres
Main finding
As reported in the abstract
Adjusted odds ratio
2.03
95% CI 1.87–2.20
P < 0.001
By group
COVID vs non-COVID
aOR 2.03 (95% CI 1.87–2.20); P < 0.001
Observational data: associations, not effects.
Secondary outcomes
LOS
P < 0.001
Age ≥ 65 years
P < 0.001
| Outcome | COVID | non-COVID | P value |
|---|---|---|---|
| Direct hospitalization cost | $207,022 ± $208,842 | $198,508 ± 205,510 | P = 0.02 |
In-hospital mortality by year (COVID)
- 2020
- 50.3%
- 2021
- 48.6%
- 2022
- 37.3%
- Precipitous drop in COVID ECMO case volume from quarter 2 of 2022
Original publication
Analysis of Veno-Venous Extracorporeal Membrane Oxygenation for COVID-19 Compared to Non-COVID Etiologies. Ann Surg. Published 16 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →